DNA Vaccines

Initial Results Announced for Improved Delivery System

Published in Gene Therapy Weekly, August 31st, 2000

BioSante Pharmaceuticals, Inc. (BTPH; BAI), Lincolnshire, Illinois, announced successful initial pre-clinical results from its collaboration with Medi-Ject Corp. (MEDJ) to develop improved drug delivery systems for DNA vaccines that combine Medi-Ject's needle-free pressure assisted injection and BioSante's vaccine adjuvant technology.

According to the company, the test results clearly demonstrated the ability of Medi-Ject's needle-free injection system to deliver BioSante's particle-based vaccine adjuvant system (CAP) to the targeted intra-muscular injection site. The tests were conducted with DNA encoding viral proteins formulated with BioSante's proprietary vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-08-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry